Every two years, a little-noticed provision of the Consumer Product Safety Act (CPSA) reshapes the regulatory reporting landscape for manufacturers and importers of consumer products in the United States. Continue Reading Consumer Product Manufacturers: Is Your Regulatory Slate Clean?
After a very difficult 2020, rapid vaccine development has sparked optimism among the public and in the business community. But as we wrote last week, there’s a long road ahead while infections remain high. Today we look at considerations for a new transition period – vaccines becoming more widely available, but before the country achieves herd immunity. Continue Reading How Companies Can Approach Wider Availability of COVID-19 Vaccines in the Coming Months
As COVID-19 cases have spiked across the country, many businesses have adjusted certain operations with an eye on customer and employee safety, as well as to ensure compliance with recent changes to government orders. Some businesses have faced challenges that they have not seen since last spring. Over the summer, we explained some ways companies could prepare for a potential winter resurgence of the virus. Today we consider how companies may wish to proceed as average daily death totals in the U.S. remain high. Continue Reading Business Considerations in Light of Increases in COVID-19 Cases
Over the last several decades, there have been significant advancements in automotive technology. Today’s vehicles are equipped with more and more sophisticated computer systems than ever before. But as our reliance on technology continues to grow, so does the potential for cybersecurity attacks and resulting litigation. That’s why it’s becoming increasingly important for car manufacturers to pay close attention to the legal landscape. Continue Reading Vehicle Manufacturers Face Cybersecurity Challenges
We are delighted to share that this blog has received a 2020 “Go-To Thought Leadership Award” by the National Law Review for providing relevant analysis, knowledge, and thorough coverage of product liability and Consumer Product Safety Commission (CPSC) enforcement issues.
Over the last few years, as the U.S. Consumer Product Safety Commission (CPSC) has moved slowly in its rulemaking efforts to address tip-overs of dressers. Without a final rule, the agency has sought to use other methods to address dresser incidents, specifically its authority to investigate potentially hazardous products and its ability to request – and even compel – recalls. The agency’s process has been straightforward: It has obtained samples of countless brands and models of dressers, tested them against the relevant voluntary standard, and, where testing suggested the samples did not meet the standard, sent letters requesting recalls. Continue Reading Regulation-by-Enforcement: CPSC Targets Adult Portable Bed Rail Industry Company-by-Company
In Illinois, the collateral source rule bars defendants from submitting evidence that plaintiffs received compensation for their injuries from a collateral source. For example, if a plaintiff is injured in a car accident due to someone else’s negligent actions, often the plaintiff’s insurance company will cover part of the plaintiff’s medical expenses even before the plaintiff files a lawsuit against the tortfeasor. In that example, the defense is prohibited from submitting evidence regarding that compensation. The purpose of this rule is to prevent defendants from reducing or eliminating the amount of damages they are liable for. On May 21, 2020, the Illinois Supreme Court defined the outer limits of this rule in Mary Lewis, et al. v. Lead Industries Association, et al. (Atlantic Richfield Company, et al.), holding that plaintiffs cannot use the collateral source rule to establish the injury element of a cause of action. The Lewis plaintiffs argued that the cost of the lead testing, which had been covered entirely by Medicaid, should be recoverable pursuant to the collateral source rule. The Court was unconvinced and ruled that pure economic loss claims in which a plaintiff cannot establish actual out-of-pocket expenses will fail and the collateral source rule will not provide the necessary support to overcome that hurdle in Illinois. Continue Reading Lewis Court Rejects the Use of the Collateral Source Rule to Establish Injury-in-Fact
Several state and federal courts have recently addressed a hot-button issue in product liability law: whether the manufacturer of a product that has an asbestos-containing replacement part that causes injury may be liable even if the manufacturer itself did not manufacture or supply the replacement part. Consider this example: a manufacturer produces a steam trap or boiler that contains an asbestos gasket that needs to be replaced from time to time. Third parties supply the replacement gaskets. Is the original product manufacturer liable for injuries allegedly caused by the asbestos-containing replacement gaskets? Continue Reading Whelan v. Armstrong Int’l, Inc.: Latest Asbestos Ruling Expands Manufacturer Liability for Injuries
In yesterday’s post, we described a scenario involving a simple traffic accident, asking you to estimate the average exposure at trial.
What is the average exposure at trial in this case, based on your counsel’s estimates of these various possible outcomes?
- $1.4 million
- $3.3 million
- $5.5 million
- $8.1 million
Legal success is driven by the correct perception of risk. Plaintiffs don’t want to leave emptyhanded, and defendants don’t want to pay more than necessary. Sometimes the facts favor only one side, but most of the time a party’s legal risks fall on a spectrum between these extremes.
Managing that spectrum effectively is critical. But when cases get complex, even great lawyers have a hard time placing values on them. We have a solution to this: MagnitudeSM, our new artificial intelligence tool that takes the good advice of your preferred lawyers about the merits of a claim and translates it into dollars. Continue Reading How to Value Important Cases: Introducing Magnitude